

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
20 October 2022 (20.10.2022)



(10) International Publication Number
WO 2022/221450 A1

(51) International Patent Classification:

A61K 31/4995 (2006.01) A61K 45/06 (2006.01)
A61K 31/501 (2006.01) C07D 487/08 (2006.01)

(21) International Application Number:

PCT/US2022/024684

(22) International Filing Date:

13 April 2022 (13.04.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/174,415 13 April 2021 (13.04.2021) US

(71) Applicant: **PIPELINE THERAPEUTICS, INC.**
[US/US]; 10578 Science Center Drive, Suite 200, San Diego, CA 92121 (US).

(72) Inventors: **ROPPE, Jeffrey**; c/o Pipeline Therapeutics, Inc., 10578 Science Center Drive, Suite 200, San Diego, CA 92121 (US). **BACCEI, Jill Melissa**; c/o Pipeline Therapeutics, Inc., 10578 Science Center Drive, Suite 200, San Diego, CA 92121 (US). **CHEN, Austin Chih-Yu**; c/o Pipeline Therapeutics, Inc., 10578 Science Center Drive, Suite 200, San Diego, CA 92121 (US). **XIONG, Yifeng**;

c/o Pipeline Therapeutics, Inc., 10578 Science Center Drive, Suite 200, San Diego, CA 92121 (US). **SCHRADER, Thomas**; c/o Pipeline Therapeutics, Inc., 10578 Science Center Drive, Suite 200, San Diego, CA 92121 (US). **BRAVO, Yalda**; c/o Pipeline Therapeutics, Inc., 10578 Science Center Drive, Suite 200, San Diego, CA 92121 (US).


(74) Agent: **LEE, Joohee** et al.; Mintz Levin Cohn Ferris Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

(54) Title: CRYSTALLINE COMPOUND OF MUSCARINIC ACETYLCHOLINE M₁ RECEPTOR ANTAGONISTS

FIG. 1



(57) Abstract: Disclosed herein, *inter alia*, are a crystalline compound of mAChR M₁ antagonist, its pharmaceutical composition and methods of treatment.

[Continued on next page]

WO 2022/221450 A1

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*